TRK fusion proteins are often oncogenic drivers in a wide variety of tumor types in both adult and pediatric patients1,2
- Research has identified NTRK gene fusions in more than 2 dozen types of common and rare solid tumors1,3-5
- The presence of TRK proteins has been associated with more aggressive cancer in some tumor types5-7
- Traditional approaches to the treatment of solid tumors are not designed to directly impact NTRK gene fusions or TRK proteins8
Even though it’s not a common alteration, learning that an NTRK gene fusion is the driver of a patient’s cancer would be a meaningful discovery.
Sign up to receive additional information.